🇺🇸 FDA
Pipeline program

JANX008

EGFR-008-001

Phase 1 small_molecule active

Quick answer

JANX008 for Non-Small Cell Lung Cancer is a Phase 1 program (small_molecule) at Janux Therapeutics with 1 ClinicalTrials.gov record(s).

Program details

Company
Janux Therapeutics
Indication
Non-Small Cell Lung Cancer
Phase
Phase 1
Modality
small_molecule
Status
active

Clinical trials